ANI Pharmaceuticals, Inc. (ANIP)
- Previous Close
60.37 - Open
60.50 - Bid 60.38 x 100
- Ask 77.05 x 200
- Day's Range
59.75 - 61.24 - 52 Week Range
52.50 - 77.00 - Volume
134,128 - Avg. Volume
401,462 - Market Cap (intraday)
1.309B - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
-- - EPS (TTM)
-1.18 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
83.00
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
www.anipharmaceuticals.com897
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ANIP
View More
Performance Overview: ANIP
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANIP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANIP
View MoreValuation Measures
Market Cap
1.31B
Enterprise Value
1.80B
Trailing P/E
--
Forward P/E
9.72
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.74
Price/Book (mrq)
3.12
Enterprise Value/Revenue
2.67
Enterprise Value/EBITDA
26.91
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.12%
Return on Assets (ttm)
0.82%
Return on Equity (ttm)
-4.57%
Revenue (ttm)
674.07M
Net Income Avi to Common (ttm)
-22.43M
Diluted EPS (ttm)
-1.18
Balance Sheet and Cash Flow
Total Cash (mrq)
155.19M
Total Debt/Equity (mrq)
142.03%
Levered Free Cash Flow (ttm)
39.8M
Research Analysis: ANIP
View MoreResearch Reports: ANIP
View MoreLowering target price to $65.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $65.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about ANIP?
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $74.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $74.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $74.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $72.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $72.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target